Day Philip J R
The University of Manchester, Centre for Integrated Genomic Medical Research (CIGMR), Stopford Building, Oxford Road, Manchester, M13 9PT, UK.
Expert Rev Mol Diagn. 2006 Jan;6(1):23-8. doi: 10.1586/14737159.6.1.23.
Despite huge efforts in sample analysis, the measurement of marker nucleic acids within tissues remains largely nonquantitative. Gene analyses have benefited from sensitivity gains through in vitro gene amplification, including PCR. However, whilst these processes are intrinsically suited to highly reproducible, accurate and precise gene measurement, the term semiquantitative analysis is still commonly used, suggesting that other fundamental limitations preclude a generic quantitative basis to gene analysis. The most poorly defined aspect of gene analysis relates to the sample itself. The amount of cells and, particularly, cell subtype composition are rarely annotated before analysis; indeed, they are often extrapolated after analysis. To advance our understanding of pathogenesis, assay formats will benefit from resembling the dimensions of the cell, to assist in the analysis of cellular components of tissue complexes. This review is partly a perspective on how current miniaturization technologies, in association with molecular biology, microfluidics and surface chemistries, may evolve from the parts of a paradigm to enable the unambiguous quantitative analysis of complex biologic matter.
尽管在样本分析方面付出了巨大努力,但组织内标志物核酸的测量在很大程度上仍是非定量的。基因分析受益于包括聚合酶链反应(PCR)在内的体外基因扩增所带来的灵敏度提升。然而,虽然这些过程本质上适合高度可重复、准确和精确的基因测量,但“半定量分析”一词仍被普遍使用,这表明其他基本限制妨碍了基因分析建立通用的定量基础。基因分析中定义最不明确的方面与样本本身有关。在分析之前,细胞数量,尤其是细胞亚型组成很少被标注;实际上,它们往往是在分析之后推断出来的。为了加深我们对发病机制的理解,分析形式将受益于与细胞尺寸相似,以协助分析组织复合体的细胞成分。本综述部分是关于当前的小型化技术如何与分子生物学、微流体学和表面化学相结合,从范式的各个部分发展,以实现对复杂生物物质的明确定量分析的观点。